YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
1 Cash-Burning Stock for Long-Term Investors and 2 Facing Headwinds Rapid spending isn't always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable. N…
Ocular Therapeutix, Inc. BEDFORD, Mass., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular" or the "Company"), an integrated biopharmaceutical company committed to redefining the retina experience, today ann…
Investing.com -- Raymond James has identified its top stock picks in the healthcare sector, highlighting companies with upcoming clinical trial results and promising drug development programs. The firm's Analyst Current Favorites list feat…
3 of Wall Street's Favorite Stocks That Fall Short Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it's important to remain skeptical because analysts face instit…
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid…
In the high-stakes realm of clinical-stage biotechnology, long-term shareholder value is fundamentally forged by pipeline assets that solve deep-seated clinical bottlenecks while offering significant pricing power and capital efficiency. O…
Ocular Therapeutix, Inc. BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular" or the "Company"), an integrated biopharmaceutical company committed to redefining the retina experience, today an…
Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPD PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
On August 3, Ocular Therapeutix (NASDAQ:OCUL) reported second-quarter 2026 financial results that read as much like a regulatory update as an earnings report. Management confirmed that AXPAXLI, its lead retinal disease candidate, remains o…
1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnati…
[AMD Abbreviation or acronym of age-related macular degeneration - eye problem in older persons. Word AMD is on foreground near eye model with stethoscope and visual acuity test on blurry background] Shidlovski * Ocular Therapeutix (OCUL […
Ocular Therapeutix, Inc. BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular" or the "Company"), an integrated biopharmaceutical company committed to redefining the retina experience, today ann…
BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has grante…
3 Healthcare Stocks with Questionable Fundamentals From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial pe…
Ocular Therapeutix, Inc. Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence as Sufficie…
3 Russell 2000 Stocks That Concern Us The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher vola…
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside. Negative cash flow can le…
Ocular Therapeutix, Inc. BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular" or the "Company"), an integrated biopharmaceutical company committed to redefining the retina experience, today ann…
3 Small-Cap Stocks with Open Questions Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small becau…
[Technology background image, graph, displaying analytical data about stock trading.] Donny DBM William Blair added Oracle (ORCL [https://seekingalpha.com/symbol/ORCL]), American Express (AXP [https://seekingalpha.com/symbol/AXP]), Ecolab…
BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming s…
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Ocular Therapeuticx, Inc. (NASDAQ:OCUL) is among the best healthcare stocks. TheFly reported on June 18 that H.C. Wainwright increased i…
Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings? Over the past six months, Ocular Therapeutix's shares (currently trading at $10.37) have posted a disappointing 18.5% loss, well below the S&P 500's 7.8% gain. This was partly…
(RTTNews) - Ocular Therapeutix Inc. (OCLU), a biopharmaceutical company, on Thursday released updates on FDA alignments achieved for the new drug application (NDA) for AXPAXLI in treating wet Age-related Macular Degeneration (wet AMD). The…
Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos Check out the companies making headlines yesterday: Nubank (NYSE:NU): Digital banking platform Nubank (NYSE:NU) rose by 3.2% on Wednesday after the…
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients of safety data across SO…
Ocular Therapeutix (NASDAQ:OCUL) and Prime Medicine (NASDAQ:PRME) represent two distinct paths within the high-risk, high-reward world of medical innovation. Choosing between them requires balancing established commercial revenue against m…
Pharmaceuticals Stocks Q1 Recap: Benchmarking Jazz Pharmaceuticals (NASDAQ:JAZZ) Let's dig into the relative performance of Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers as we unravel the now-completed Q1 pharmaceuticals earnings season…
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek…
Ocular Therapeutix, Inc. BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today ann…
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size…
According to the SEC filing dated May 15, Acuta Capital Partners, LLC disclosed a first-quarter sale of 460,887 shares of Ocular Therapeutix(NASDAQ:OCUL). Reduced Ocular Therapeutix holdings by 460,887 shares Post-trade: 592,108 shares hel…
Looking back on pharmaceuticals stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Elanco (NYSE:ELAN) and its peers. The pharmaceuticals sector develops, manufactures, and distributes drugs, benefiting from…
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ANI Pharmaceuticals (NASDAQ:ANIP) and the best and worst performers in the pharmac…
Key Points Saturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million. Meanwhile, the quarter-end position value declined by $18.27 million, reflecting both share sales and…
On May 15, 2026, Saturn V Capital Management disclosed a full exit from Ocular Therapeutix(NASDAQ:OCUL), selling 1,504,880 shares in a trade estimated at $14.34 million based on quarterly average pricing. What happened According to an SEC…